Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
23.8
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales6,365¥ millionYear on year +8.1%Progress 24.7%
Operating profit1,266¥ millionYear on year +23.8%Progress 29.4%
Ordinary income1,300¥ millionYear on year +21.7%Progress 29.5%
Net income attributable to owners of the parent523¥ millionYear on year +33.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥36.15
Financial position at period-end
Total assets52,855¥ million
of which net assets 46,645 ¥ millionEquity ratio 88.3%vs. prior year-end +0.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥25,800 million (YoY +8.5%)
Operating profit¥4,300 million (YoY +0.6%)
Ordinary income¥4,400 million (YoY -1.9%)
Profit attributable to owners of the parent¥2,850 million (YoY -5.2%)
Annual Dividend Forecast¥100 → ¥100（0.0%）
Factors Behind Changes in Business Performance
The Company focused on expanding sales of safety-enhancing and high-value-added products in Japan and sales of intravenous catheters and other products overseas. Sales by product category were ¥2,087 million for dialysis products, ¥2,247 million for intravenous catheters and ¥2,020 million for interventional products.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationAdded: 0 companies; excluded: 0 companies
Material subsequent eventsT.G. Medical Co., Ltd. became a consolidated subsidiary through the acquisition of its shares announced on 3 July 2026. The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial.
Breakdown of extraordinary income (loss)Extraordinary income None / Extraordinary loss Loss on Disposal of Fixed Assets ¥101 thousand
Depreciation and amortization¥484,302 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End15,880,000 shares
Treasury Shares at Period-End1,401,913 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥6,365 million (YoY +8.1%) |
| Operating profit | ¥1,266 million (YoY +23.8%) |
| Ordinary income | ¥1,300 million (YoY +21.7%) |
| Profit attributable to owners of the parent | ¥523 million (YoY +33.5%) |
| Net income per share | ¥36.15 |
| Equity ratio | End of the current fiscal period 88.3% / End of previous period 87.8% |
| Total assets | ¥52,855 million |
| Net assets | ¥46,645 million |
| Full-year earnings forecast | Net Sales ¥25,800 million (YoY +8.5%) / Operating profit ¥4,300 million (YoY +0.6%) / Ordinary income ¥4,400 million (YoY -1.9%) / Profit attributable to owners of the parent ¥2,850 million (YoY -5.2%) |
| Annual Dividend Forecast | ¥100 → ¥100（0.0%） |
| Depreciation and amortization | ¥484,302 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Loss on Disposal of Fixed Assets ¥101 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Material subsequent events | T.G. Medical Co., Ltd. became a consolidated subsidiary through the acquisition of its shares announced on 3 July 2026. The impact on consolidated results for the fiscal year ending March 2027 is expected to be immaterial. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 15,880,000 shares |
| Treasury Shares at Period-End | 1,401,913 shares |
| Factors Behind Changes in Business Performance | The Company focused on expanding sales of safety-enhancing and high-value-added products in Japan and sales of intravenous catheters and other products overseas. Sales by product category were ¥2,087 million for dialysis products, ¥2,247 million for intravenous catheters and ¥2,020 million for interventional products. |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company worked to expand sales of safety-enhancing and high-value-added products in Japan, while pursuing sales expansion of intravenous catheters, dialysis products and interventional products overseas.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.